| |
| | Progress in the Systemic Treatment of Advanced Soft-Tissue Sarcomas (Site not responding. Last check: 2007-09-18) |
 | | The two most active single agents for advanced soft-tissue sarcomas are doxorubicin and ifosfamide with objective regression rates of 15% to 30%. |
 | | The outcome of chemotherapy for advanced soft-tissue sarcomas may be influenced by multiple factors, including type of sarcoma, tumor burden, tumor grade, metastatic pattern, performance status and, of course, the type and intensity of the treatment itself (Table 1). |
 | | Since patients with advanced soft-tissue sarcomas are in general not cured with single-modality treatments, attempts at combining chemotherapy, radiation, and surgery are necessary. |
| www.moffitt.usf.edu /pubs/ccj/v5n1/article4.html (3797 words) |
|